Discovery bioanalysis

Unlock the full potential of your molecule with our bioanalytical DMPK services

Optimise your molecule with our bioanalytical DMPK services, designed to provide high-quality quantitation of drugs and their metabolites in various biological matrices. Our laboratories offer a range of analytical techniques, including liquid chromatography–tandem mass spectrometry (LC–MS/MS), to quantify drugs such as protein-targeting chimeras (PROTAC®s), small molecules adhering to the extended rule of five, macrocycles, peptides and hormones. Additionally, we offer quantitative analysis of endogenous metabolites (biomarkers) as part of a targeted metabolomics approach in plasma, urine, tissues and other biological matrices.  

Our expertise in multiple processing techniques, including protein precipitation, liquid–liquid extraction, solid-phase extraction, derivatisation and column switching, allows us to develop optimal methods for each project’s requirements. Upon request, we can develop and validate bioanalytical methods according to guidelines across various species and matrices from non-clinical studies. Our DMPK discovery bioanalysis services support the stages of drug discovery from lead confirmation and lead optimisation to preclinical studies. We offer a comprehensive range of services, including pharmacokinetic (PK) and pharmacodynamic (PD) analysis, including metabolites, as well as toxicokinetic analysis. Our trained and highly skilled professionals work closely with you to design customised studies to meet your specific goals and timelines. We are committed to providing high-quality data and timely reports to support your drug discovery decisions. Our non-GLP DMPK services are available as an integrated drug discovery platform or as a stand-alone service.